02/07/2012 07:35:00

Glaxo, Theravance Get Positive Results From LAMA/LABA (UMEC/VI) in COPD

Related content
07 Sep - 
GSK Exercises Option over SPEAR T-cell Therapy Program ..
09 Jan - 
Adaptimmune confirms GSK Nomination of Second Adaptimmu..
05 Dec - 
Adaptimmune Announces Initiation of Myxoid/Round Cell L..

LONDON--GlaxoSmithKline PLC (GSK.LN) and Theravance, Inc. (THRX) Monday announced positive results from four pivotal phase III studies for once-daily LAMA/LABA (UMEC/VI) in COPD

MAIN FACTS:

-The results of four pivotal phase III studies of investigational LAMA/LABA involving over 4,000 patients with chronic obstructive pulmonary disease.

-These four studies include two 24-week efficacy studies that compared the combination LAMA/LABA, its components and placebo and two 24-week active comparator studies that compared the combination with the LAMA tiotropium, a widely prescribed maintenance bronchodilator for COPD.

-LAMA/LABA is a combination of two investigational bronchodilator molecules - GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist and vilanterol, a long-acting beta2 agonist, administered by a new dry powder inhaler.

-UMEC/VI is a once-daily investigational medicine currently under development for the maintenance treatment of COPD.

-Write to Razak Musah Baba at razak.baba@dowjones.com

(END) Dow Jones Newswires

July 02, 2012 02:35 ET (06:35 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Dimensional Fund Advisors Ltd. : Form 8.3 - John Wood Group Plc - Ordinary shares

21/09/2017 10:20:38
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Dimensional Fund Advisors Ltd. ("Dimensional"), in its capacity ..

P. Schoenfeld Asset Management LLP : Form 8.3 - Booker Group plc

20/09/2017 15:00:11
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: P. Schoenfeld Asset Management LLP (b) Owner or..

Invesco Ltd. : Form 8.3 - Tesco Plc

20/09/2017 13:57:19
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Invesco Ltd. (b) Owner or control..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $50 Million of Common Stock
2
Student Transportation Inc. Reports Fourth Quarter & Fiscal Year 2017 Results
3
Telenor completes its sell-down in VEON
4
MotivAction Again Named as One of the Top 25 Meeting and Incentive Companies on MeetingsNet CMI 25 List
5
Penn Virginia to Participate in Johnson Rice Conference

Related stock quotes

Glaxosmithkline PLC ORD .. 1,463.50 0.7% Stock price increasing
GlaxoSmithKline PLC 40.18 0.0% Stock price unchanged

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 September 2017 13:16:33
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170921.1 - EUROWEB5 - 2017-09-21 14:16:33 - 2017-09-21 13:16:33 - 1000 - Website: OKAY